Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies

Genome Medicine

Volumn 8, Issue 1, 2016, Pages

  Jafri, Mohammad A ^a   Ansari, Shakeel A ^a   Alqahtani, Mohammed H ^a   Shay, Jerry W ^a,b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GRNVAC 1; IMETELSTAT; NILOTINIB; PEPTIDE VACCINE; TELOMERASE; TERTOMOTIDE; UNCLASSIFIED DRUG; VX 001; ANTINEOPLASTIC AGENT; ATRX PROTEIN, HUMAN; DAXX PROTEIN, HUMAN; DNA HELICASE; ENZYME INHIBITOR; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TERT PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME REACTIVATION; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; GENE MUTATION; HUMAN; IMMUNOSTIMULATION; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; MUTATION RATE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; TELOMERE; TELOMERE HOMEOSTASIS; THROMBOCYTHEMIA; THROMBOCYTOPENIA; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; MUTATION; NEOPLASMS; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; DNA HELICASES; ENZYME INHIBITORS; HUMANS; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; TELOMERASE; TELOMERE; TELOMERE HOMEOSTASIS;

EID: 84977623281     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-016-0324-x     Document Type: Review

References (108)

1. Akincilar SC, Unal B, Tergaonkar V. Reactivation of telomerase in cancer. Cell Mol Life Sci. 2016;73:1659-70.
2. Shay JW. Are short telomeres predictive of advanced cancer? Cancer Discov. 2013;3:1096-8.
3. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959-61.
4. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957-9.
5. Vinagre J, Almeida A, Popula H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185.
6. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110:6021-6.
7. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, et al. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science. 2015;347:1006-10.
8. Picariello L, Grappone C, Polvani S, Galli A. Telomerase activity: an attractive target for cancer therapeutics. World J Pharmacol. 2014;3:86-96.
9. Klewes L, Vallente R, Dupas E, Brand C, Gru D, Guffei A, et al. Three-dimentional nuclear telomere organization in multiple myeloma. Transl Oncol. 2013;6:749-56.
10. Doksani Y, Wu JY, de Lange T, Zhuang X. Super-resolution fluorescence imaging of telomeres reveals TRF2-dependent T-loop formation. Cell. 2013;155:345-56.
11. Arnoult N, Karlseder J. Complex interaction between the DNA-damage response and mammalian telomeres. Nat Struct Mol Biol. 2015;22:859-66.
12. Zimmermann M, Kibe T, Kabir S, de Lange T. TRF1 negotiates TTAGGG repeat-associated replication problems by recruiting the BLM helicase and the TPP1/POT1 repressor of ATR signaling. Gene Dev. 2014;28:2477-91.
13. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature. 2007;448:1068-71.
14. Frescas D, de Lange T. TRF2-tethered TIN2 can mediate telomere protection by TPP1/POT1. Mol Cell Biol. 2014;34:1349-62.
15. Frescas D, de Lange T. Binding of TPP1 protein to TIN2 protein is required for POT1 protein-mediated telomere protection. J Biol Chem. 2014;289:24180-7.
16. Janouskova E, Necasova I, Pavlouskova J, Zimmermann M, Hluchy M, Marini V, et al. Human Rap 1 modulates TRF2 attraction to telomeric DNA. Nucleic Acids Res. 2015;43:2691-700.
17. Pedram M, Sprung CN, Gao Q, Lo AW, Reynolds GE, Murnane JP. Telomere position effect and silencing of transgenes near telomeres in the mouse. Mol Cell Biol. 2006;26:1865-78.
18. Robin JD, Ludlow AT, Batten K, Magdinier F, Stadler G, Wagner KR, et al. Telomere position effect: regulation of gene expression with progressive telomere shortening over long distances. Genes Dev. 2014;28:2464-76.
19. Cusanelli E, Chartrand P. Telomeric repeat-containing RNA TERRA: a noncoding RNA connecting telomere biology to genome integrity. Front Genet. 2015;6:143.
20. Arora R, Lee Y, Wischnewski H, Brun CM, Schwarz T, Azzalin CM. RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells. Nat Commun. 2014;5:5220.
21. Eid R, Demattei MV, Episkopou H, Auge-Gouillou C, Decottignies A, Grandin N, Charbonneau M. Genetic inactivation of ATRX leads to a decrease in the amount of telomeric cohesin and of telomere transcription in human glioma cells. Mol Cell Biol. 2015;35:2818-30.
22. Bourgeron T, Xu Z, Doumic M, Teixeira MT. The asymmetry of telomere replication contributes to replicative senescence heterogeneity. Sci Rep. 2015;5:15326.
23. Wright WE, Pereira-Smith OM, Shay JW. Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol Cell Biol. 1989;9:3088-92.
24. Hayashi MT, Cesare AJ, Rivera T, Karlseder J. Cell death during crisis is mediated by mitotic telomere deprotection. Nature. 2015;522:492-6.
25. Castro-Vega LJ, Jouravleva K, Ortiz-Montero P, Liu WY, Galeano JL, Romero M, et al. The senescent microenvironment promotes the emergence of heterogeneous cancer stem-like cells. Carcinogenesis. 2015;36:1180-92.
26. Shay JW, Wright WE. Role of telomeres and telomerase in cancer. Semin Cancer Biol. 2011;21:349-53.
27. Dilley RL, Greenberg RA. Alternative telomere maintenance and cancer. Trends Cancer. 2015;1:145-56.
28. Napier CE, Huschtscha LI, Harvey A, Bower K, Noble JR, Hendrickson EA, et al. ATRX represses alternative lengthening of telomeres. Oncotarget. 2015;6:16543-58.
29. O'Sullivan RJ, Almouzni G. Assembly of telomeric chromatin to create alternative endings. Trends Cell Biol. 2014;24:675-85.
30. Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 2015;347:273-7.
31. Zhang Q, Kim NK, Feigon J. Architecture of human telomerase RNA. Proc Natl Acad Sci U S A. 2011;108:20325-32.
32. Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, et al. Telomerase directly regulates NF-kB-dependent transcription. Nat Cell Biol. 2012;14:1270-81.
33. Koh CM, Khattar E, Leow SC, Liu CY, Muller J, Ang WX, et al. Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J Clin Invest. 2015;125:2109-22.
34. Liu H, Liu Q, Ge Y, Zhao Q, Zheng X, Zhao Y. hTERT promotes cell adhesion and migration independent of telomerase activity. Sci Rep. 2016;6:22886.
35. Liu Z, Li K, Chen L, Li W, Hou M, Liu T, et al. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene. 2013;32:4203-13.
36. Masutomi K, Kaneko S, Hayashi N, Yamashita T, Shirota Y, Kobayashi K, Murakami S. Telomerase activity reconstituted in vitro with purified human telomerase reverse transcriptase and human telomerase RNA component. J Biol Chem. 2000;275:22568-73.
37. Venteicher AS, Abreu EB, Meng Z, McCann KE, Terns RM, Veenstra TD, et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science. 2009;323:644-8.
38. Veinteicher AS, Meng Z, Mason PJ, Veenstra TD, Artandi SE. Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme activity. Cell. 2008;132:945-57.
39. Hockemeyer D, Collins K. Control of telomerase action at human telomeres. Nat Struct Mol Biol. 2015;22:848-52.
40. Schmidt JC, Dalby AB, Cech TR. Identification of human TERT elements necessary for telomerase recruitment to telomeres. Elife. 2014;3:e03563.
41. Lee JH, Jeong SA, Khadka P, Hong J, Chung IK. Involvement of SRSF 11 in cell cycle-specific recruitment of telomerase to telomeres at nuclear speckles. Nucleic Acids Res. 2015;43:8435-51.
42. Schmit JC, Cech TR. Human telomerase: biogenesis, trafficking, recruitment and activation. Genes Dev. 2015;29:1095-105.
43. Hsu C, Lee L, Tang S, Hsin I, Lin Y, Ko J. Epidermal growth factor activates telomerase activity by direct binding of Ets-2 to hTERT promoter in lung cancer cells. Tumor Biol. 2015;36:5389-98.
44. Chan AK, Yao Y, Zhenyu Z, Chung NY, Liu JS, Ka-Wai, et al. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Modern Pathol. 2015;28:177-86.
45. Huang FW, Bielski CM, Rinne ML, Hahn WC, Seller WR, Stegmeier F, et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015;4:e176.
46. Heidenreich B, Rachakondan PS, Hemmink K, Kumar R. TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014;24:30-7.
47. Allory Y, Beukers W, Sagrera A, Flandez M, Marquez M, van der Keur KA, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014;65:360-6.
48. Huang D, Wang Z, Heb XJ, Diplas BH, Yang R, Killela PJ. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumor types are associated with increased TERT expression and telomerase activation. Eur J Cancer. 2015;51:969-76.
49. Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D. Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife. 2015;4:e7918.
50. Bell RJA, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, et al. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015;348:1036-9.
51. Li Y, Zhou Q, Sun W, Chandrasekharan P, Cheng H, Ying Z. Non-canonical NF-kB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat Cell Biol. 2015;17:1327-38.
52. Stoer R, Taubert H, Zinnall U, Giedl J, Gaisa NT, Burger M, et al. Frequency of TERT promoter mutations in prostate cancer. Pathobiology. 2015;82:53-7.
53. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev. 2002;66:407-25.
54. Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman FT, Lobanenkov V, et al. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res. 2007;35:1245-56.
55. Lai SR, Phipps SM, Liu L, Andrews LG, Tollefsbol TO. Epigenetic control of telomerase and modes of telomere maintenance in aging and abnormal systems. Front Biosci. 2005;10:1779-96.
56. Wong MS, Wright WE, Shay JW. Alternative splicing regulation of telomerase: a new paradigm. Trends Genet. 2014;30:430-8.
57. Buseman CM, Wright WE, Shay JW. Is telomerase a viable target in cancer? Mutat Res. 2012;730:90-7.
58. Bryan C, Rice C, Hoffman H, Harkisheimer M, Sweeney M, Skordalakes E. Structural basis of telomerase inhibition by the highly specific BIBR1532. Structure. 2015;23:1934-42.
59. Cruz J, Wojdyla L, Ivancich M, Puri N. Targeting the telomere with T-oligo, G-quadruplex stabilizers, and tankyrase inhibitors. J Cancer Sci Ther. 2014;6:10.
60. Jackson SR, Zhu CH, Paulson V, Watkins L, Dikmen ZG, Gryaznov SM, et al. Antiadhesive effects of GRN163L-an oligonucleotide N3'→P5' thio-phosphoramidate targeting telomerase. Cancer Res. 2007;67:1121-9.
61. Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, et al. Lipid modification of GRN163, an N3'→P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005;24:5262-8.
62. Marian CO, Wright WE, Shay JW. The effects of telomerase inhibition on prostate tumor-initiating cells. Int J Cancer. 2010;127:321-31.
63. Burchett KM, Yan Y, Ouellette MM. Telomerase inhibitor imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. PLoS One. 2014;9:e85155.
64. Hu Y, Bobb D, He J, Hill AD, Dome JS. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma. Cancer Biol Ther. 2015;16:949-57.
65. Dikmen ZG, Gellert GC, Jackson SR, Gryaznov SM, Tressler R, Dogan P, et al. In vivo inhibition of lung cancer by GRN163L: a novel telomerase inhibitor. Cancer Res. 2005;65:7866-73.
66. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res. 2010;16154-63.
67. Lu R, Pal J, Buon L, Nanjappa P, Shi J, Fulciniti M, et al. Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. Oncogene. 2014;33:1495-505.
68. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10:673-9.
69. Lev A, Denkberg G, Cohen CJ, Tzukerman M, Skorecki KL, Chames P, et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 2002;62:3184-94.
70. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 2002;21:674-9.
71. Vonderheide RH. Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie. 2008;90:173-80.
72. Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2013;39:444-56.
73. Kyte JA. Cancer vaccination with telomerase peptide. Expert Opin Investig Drugs. 2009;18:687-94.
74. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-grimsrud CJ, Sve I, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2006;55:1553-64.
75. Georgoulias V, Douillard JY, Khayat D, Manegold C, Rosell A, Menez-Jamet J, et al. A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. Clin Lung Cancer. 2013;14:461-6.
76. + non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Lung Cancer. 2014;86:59-66.
77. Ouellette MM, Wright WE, Shay JW. Targeting telomerase-expressing cancer cells. J Cell Mol Med. 2011;15:1433-42.
78. + T cell responses in patients with metastatic prostate cancer. J Immunol. 2005;174:3798-807.
79. Mender I, Gryaznov S, Dikmen ZG, Wright WE, Shay JW. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine. Cancer Discov. 2015;5:82-95.
80. Mender I, Gryaznov S, Shay JW. A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not in telomerase silent normal cells. Oncoscience. 2015;2:693-5.
81. Muller HJ. The remaking of chromosomes. Collecting Net. 1938;13:181-98.
82. McClintock B. The stability of broken ends of chromosomes in Zea mays. Genetics. 1941;26:234-82.
83. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585-621.
84. Watson JD. Origin of concatemeric T7 DNA. Nat New Biol. 1972;239:197-201.
85. Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol. 1973;41:181-90.
86. Blackburn EH, Gall JG. A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena. J Mol Biol. 1978;120:33-53.
87. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985;43:405-13.
88. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989;59:521-9.
89. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-5.
90. Bodnar AG, Ouellete M, Frolkis M, Holt SE, Chiu C-P, Morin GB, et al. Extension of lifespan by introduction of telomerase in normal human cells. Science. 1998;279:349-52.
91. Clynes D, Jelinska C, Xella B, Ayyub H, Scott C, Mitson M, et al. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX. Nat Commun. 2015;6:7538.
92. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333:425.
93. Bower K, Napier CE, Cole SL, Dagg RA, Lau LMS, Duncan EL, et al. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of alternative lengthening of telomeres. PLoS One. 2012;7:e50062.
94. Nakashima M, Nandkumar J, Sullivan KD, Espinosa JM, Cech TR. Inhibition of telomerase recruitment and cancer cell death. J Biol Chem. 2013;288:33171-80.
95. Li Y, Tergaonkar V. Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies. Cancer Res. 2014;74:1639-44.
96. G12V -induced lung cancer by induction of telomeric DNA damage. EMBO Mol Med. 2015;7:930-49.
97. Lee SS, Bohrson C, Pike AM, Wheelan SJ, Greider CW. ATM kinase is required for telomere elongation in mouse and human cells. Cell Rep. 2015;13:1623-32.
98. Tong AS, Stern JL, Sfeir A, Kartawinata M, de Lange T, Zhu XD, et al. ATM and ATR signaling regulate the recruitment of human telomerase to telomeres. Cell Rep. 2015;13:1633-46.
99. Jansson LI, Akiyama BM, Ooms A, Lu C, Rubin SM, Stone MD. Structural basis of template-boundary definition in Tetrahymena telomerase. Nat Struct Mol Biol. 2015;22:883-8.
100. Rachkonda PS, Hosen I, de Verdier PJ, Fallah M, Heideneich B, Ryk C, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A. 2013;110:17426-31.
101. Wang K, Liu T, Liu L, Liu J, Liu C, Wang C, et al. TERT promoter mutations in renal cell carcinoma and upper tract urothelial carcinomas. Oncotarget. 2014;5:1829-36.
102. Wang K, Liu T, Ge N, Liu L, Yuan X, Liu J, et al. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. Oncotarget. 2014;5:12428-39.
103. Cevlik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol. 2015;21:311-17.
104. Vinagre J, Pinto V, Celestino R, Reis M, Populo H, Boaventura P, et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch. 2014;465:119-33.
105. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20:603-10.
106. Koelsche C, Renner M, Hartmann W, Brandt R, Lehner B, Waldburger N, et al. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res. 2014;33:33.
107. Koelsche C, Sahm F, Capper D, Reuss D, Stum D, Jones DT, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol. 2013;126:907-15.
108. Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer: an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15:829-40.